Takeda, Frazier Healthcare Partners to launch Phathom Pharma
Takeda Pharmaceutical and Frazier Healthcare Partners have announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and... Read More
Novatis’s Xiidra acquisition from Takeda for USD 5.3 billion
Novartis has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra (lifitegrast ophthalmic solution) 5%... Read More
Glenmark to introduce SGLT2 inhibitor Remogliflozin in India by licesning collaboration with BHV Pharma
Glenmark Pharmaceuticals is bringing to India Remogliflozin etabonate, a drug used to treat adults with Type 2 diabetes. Glenmark did the phase... Read More
DRL sells brand Sernivo; grants Promiseb and Trianex US marketing rights to Encore Dermatology
Posted on03 Apr 2019
Comments0
Dr. Reddy’s Laboratories Limited through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for Sernivo (betamethasone dipropionate)... Read More
Check Your Competency in Data Integrity
Data Integrity refers to maintaining and assuring the accuracy and consistency of data over its entire product life-cycle. Over the last few years several, FDA... Read More
Lilly, ImmuNext licensing deal for R&D collaboration
Eli Lilly and Company and ImmuNext, Inc. announced a global licensing and research collaboration focused on the study of a preclinical novel... Read More
GSK’s Advair Loss of Exclusivity (LOE) and Mylan’s Wixela Inhub generic entry
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the GlaxoSmithKline’s respiratory blockbuster, Advair. ... Read More
Roche to acquire U.S.-Based Gene Therapy Specialist Spark @ $4.8 Billion
Swiss drugmaker Roche agreed to buy Philadelphia-based Spark Therapeutics for $4.8 billion. Spark works to create gene therapies for genetic diseases, including... Read More
Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
Merck to acquire immunotherapy company, Immune Design for US$ 300 million
Merck and Immune Design announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire... Read More